Page 14 - Haematologica Vol. 110 - January 2025

PROS AND CONS EDITORIAL
E. Copelan and R.P. Gale
correlation between people drowning after falling out of a fishing boat and marriage rate in Kentucky. Bone Marrow Transplant. 2020;55(1):1-3.
12. Meuser M, Ofran Y, Boissel N, et al. Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(6):697-712.
13. Thol F, Heuser M. Treatment of relapsed acute myeloid leukemia. Curr Treat Options Oncol. 2020;21(8):66.
14. Dohner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345-1377.
15. Thol F, Dohner H, Ganser A. How I treat refractory and relapsed acute myeloid leukemia. Blood. 2024;143(1):11-20.
16. National Comprehensive Cancer Network Guidelines, 2024. www.nccn.org/guidelines/category_1 Accessed June 4, 2024
17. Barosi G, Gale RP. Is there expert consensus on expert consensus? Bone Marrow Transplant. 2018;53(8):1055-1060.
18. Barosi G, Gale RP. Everyone is entitled to his or her own opinion but not to their own facts. Br J Haematol. 2022;196(6):1290-1292.
19. Sharma A, Logan B, Estrada-Merly N, et al. Impact of public reporting of center-specific survival analysis scores on patient
volumes at hematopoietic cell transplant centers. Transplant
Cell Ther. 2023;29(8):523-528.
20. de Cordova PB, Johansen ML, Riman KA, Rogowski J. Public
reporting of cardiac outcomes for patients with acute myocardial infarction: a systematic review of the evidence. J Cardiovasc Nurs. 2019;34(2):115-123.
21. Andreoni KA. Kidney transplant program specific reporting and transplant metrics. Curr Opin Organ Transplant. 2022;27(1):70-74.
22. Sorror ML. Initial steps towards improving quality of care for allogenic hematopoietic cell transplantation recipients at individual centers. Transplant Cell Ther. 2023;29(8):482-483.
23. Stelljes M, Middeke JM, Bug G, et al. Remission induction versus immediate allogenic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomized, open-label, phase 3, non- inferiority trial. Lancet Haematol. 2024;11(5):e324-e335.
24. Forman, SJ, Rowe JM. The myth of the second remission of acute leukemia in the adult. Blood. 2013;121(7):1077-1082.
25. Gale RP, Phillips GL, Lazarus HM. A modest proposal to the transplant publik to prevent harm to people with acute myeloid leukaemia in 1st complete remission cured by chemotherapy. Leukemia. 2024;38(8):1663-1666.
Haematologica | 110 January 2025
6